$27.11 -0.85 (-3.04%)
11/27/2009 1:00 PM

Human Genome Sciences (HGSI)

CAPS Rating: 2 out of 5

The drug development company with three products advancing into late-stage clinical development: Albuferon(r) for chronic hepatitis C, LymphoStat-B(r) for systemic lupus erythematosus, and ABthraxtm for anthrax disease.

Results 1 - 20 of 92 1 2 3 4 5 Next »

Recs

0
Member Avatar ultimategirl1963 (78.66) Submitted: 11/26/2009 6:02:20 AM : Outperform Start Price: $27.08 HGSI Score: -0.97

:)

Recs

0
Member Avatar golfer121501 (93.76) Submitted: 11/16/2009 1:10:55 PM : Underperform Start Price: $27.36 HGSI Score: -0.37

Following Ultralong

Recs

0
Member Avatar Timbofittz88 (< 20) Submitted: 11/16/2009 12:19:12 PM : Underperform Start Price: $28.03 HGSI Score: +1.95

going down!

Recs

0
Member Avatar IFindKaching (< 20) Submitted: 11/12/2009 10:17:30 AM : Outperform Start Price: $28.10 HGSI Score: -3.64

Given the dearth of success in attacking Lupus, and the promise of HGSI's Benlysta, the sky is truly the limit for this company. Additionally, the road that HGSI has followed to achieve this milestone is replicable for other, similar, autoimmune diseases and could provide an enticing pipeline for a large pharma takeover.

Recs

0
Member Avatar WAKEUPANDSMELL (24.32) Submitted: 11/9/2009 10:05:07 PM : Outperform Start Price: $28.20 HGSI Score: -4.10

DEFINE TAKEOVER

Recs

0
Member Avatar pjani06 (98.15) Submitted: 11/4/2009 10:22:50 PM : Underperform Start Price: $26.60 HGSI Score: +1.78

stock that has shot up alot in past year yet are in CAPs.

Recs

0
Member Avatar TraderHater (52.48) Submitted: 11/4/2009 4:17:39 PM : Underperform Start Price: $26.60 HGSI Score: +1.78

Still crap

Recs

0
Member Avatar jwhitehead1 (< 20) Submitted: 11/3/2009 8:33:29 PM : Outperform Start Price: $27.61 HGSI Score: -5.66

Beyond the expectation that GSK will make an offer on HGSI late 2Q or early 3Q, 3 billion in potential goes a long way towards this company beating the street and Benylsta isn't the only pony in the stable.

Recs

0
Member Avatar oghowie (88.04) Submitted: 11/3/2009 7:01:19 PM : Underperform Start Price: $27.61 HGSI Score: +5.66

Huge run up after test results. Wait for it to correct and rebuy after 20%. Same thing happened after the last positive test results.

Recs

0
Member Avatar cashsage (96.87) Submitted: 11/3/2009 4:05:03 AM : Underperform Start Price: $24.27 HGSI Score: -6.08

HGSI has a too high valuation compared to its sales potential. It is also loss making at least until 2010.

Recs

0
Member Avatar earthunit (58.88) Submitted: 11/2/2009 7:23:54 PM : Underperform Start Price: $24.27 HGSI Score: -6.08

Totally over-rated drug for MS. 43% of patients improved on their so-called HOT MS drug vs. 33% improving on placebo.
NOT impressive. Company's Anthrax drug just bombed.
Stock overvalued.

Recs

0
Member Avatar uclayoda87 (30.65) Submitted: 11/1/2009 3:46:15 AM : Underperform Start Price: $19.74 HGSI Score: -34.26

In good financial times speculative biotech companies have time and money to develop the next block buster drug. With the health care changes and financial uncertainty these biotech companies won't be given much time to prove themselves.

Recs

0
Member Avatar hymettus (48.93) Submitted: 10/30/2009 12:39:18 PM : Outperform Start Price: $20.00 HGSI Score: +30.75

This is a great longterm buy. Wait till the full value of this company is realized. Plus it might have some other great trial results! This stock will easily return 50% in a year. A great/ reasonably safe buy

Recs

0
Member Avatar tctk1044 (20.34) Submitted: 10/26/2009 8:44:19 AM : Outperform Start Price: $19.76 HGSI Score: +35.93

Testing Schaeffer on a short

Recs

0
Member Avatar TREVGPAYNE (< 20) Submitted: 10/14/2009 3:33:49 PM : Outperform Start Price: $19.17 HGSI Score: +41.21

I feel confident HGSI will soon conclude another successful Phase III trial and consequently will receive FDA approval to bring their drug for Lupus to market. Once that happens the stock will take off to new highs.
.

Recs

0
Member Avatar moneyman132 (22.67) Submitted: 10/11/2009 2:44:17 PM : Outperform Start Price: $18.60 HGSI Score: +44.07

The pharmaceutical company Human Genome Sciences has consistently been coming out with groundbreaking medicines and cures for dangerous diseases. Their stock went from around $0.85 to $20 in just a few months with the release of one drug. They have many more in late stage development and some others almost in production. I think that HGSI will continue to rise with the production of more new medicines. This is a good pick for the future.

Recs

1
Member Avatar DarthMaul09 (98.58) Submitted: 10/8/2009 2:35:36 AM : Underperform Start Price: $19.01 HGSI Score: -39.77

Even if the company can get its drug to market, the market for these drugs is small and the government efforts to control costs will also limit the potential profits of these small drug companies.

Recs

0
Member Avatar tuscanstar (51.26) Submitted: 9/22/2009 3:28:07 PM : Outperform Start Price: $19.50 HGSI Score: +36.73

The company has three late-stage products sure to become great earnings producers. The current progress of its Lupus medication alone holds great potential, even against competitor advances.

Recs

0
Member Avatar d0319a (55.70) Submitted: 9/22/2009 9:21:55 AM : Outperform Start Price: $19.82 HGSI Score: +34.42

lupus drug

Recs

0
Member Avatar ArgusPanoptes (< 20) Submitted: 9/21/2009 2:19:34 AM : Underperform Start Price: $19.80 HGSI Score: -33.44

A superficial look shows me a catchy name with a lot of red ink of their books.

Results 1 - 20 of 92 1 2 3 4 5 Next »

Featured Broker Partners